A Phase 3 interventional study of ranibizumab in Choroidal Neovascularization, Macular Edema and Glaucoma, Neovascular, sponsored by Novartis Pharmaceuticals. Completed at 39 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 10th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 35th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
29 studies in Choroidal Neovascularization by Novartis: none open now, none under way, none of them phase 3. Of 29 finished, 22 (76%) have results posted.
Among the 29 studies in Choroidal Neovascularization by Novartis, this one is the 9th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2013, is one of 14 in phase 3, and was the 17th registered.
Novartis’s Choroidal Neovascularization studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 29 in Choroidal Neovascularization:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
Drug: ranibizumab
One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) for ocular and non-ocular events. Due to early termination, only descriptive analysis was conducted.
Time frame: 24 months
Change From Baseline Best Corrected Visual Acuity (BCVA) for Patients With Choroidal Neovascularization (CNV) and Macular Edema (ME)
BCVA change for diseases affecting the macular area either through CNV or ME. BCVA is tested using the ETDRS (Early Treatment Diabetic Retinopathy Study), the Snellen or Monoyer scales. The three scales are designed to measure visual acuity. ETDRS score is expressed in letter, Snellen and Monoyer score in fraction. BCVA assessment is presented in ETDRS after conversion if collected in Snellen or Monoyer. (Monoyer converted to Snellen = 2 x (Monoyer fraction) and Snellen converted to approximate ETDRS letters = 1x log(Snellen fraction). ETDRS letter score was transformed in logMAR unit for statistical analysis (- LogMAR = -(ETDRS-85)/50). The worse ETDRS letter score is 0 (logMAR 2.3) and the best ETDRS letter score is 100 (logMAR -0.3).
Time frame: 3 months, 12 months
Average Change of Neovascularization Extension for Patients With Neovascular Glaucoma
The extent of iris neovascularization was assessed by iris photography and graded using the "Teich and Walsh grading system". This grading system measures the number of quadrant at iris pupillary zone or iris ciliary zone where iris neovascularization (NV) is observed. Grade 0 = "No iris vascularization", Grade 1= Less than 2 quadrants of NV at iris pupillary zone, Grade 2 = More than 2 quadrants of NV at iris pupillary zone, Grade 3 =Grade 2 + less than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae; Grade 4 =More than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae)
Time frame: 3 month, 12 month
Proportion of Patient With Vitreous Cavity Hemorrhage Occurrence for Patient With Proliferative Retinopathy
Occurrence of postoperative vitreous cavity hemorrhage
Time frame: 3 months, 12 month
Mean Change From Baseline in Change in Central Retinal Thickness for Patients With CNV (Choroidal Neovascularization) and ME (Macular Edema)"
CRT in micrometers assessed by Optical Tomography (OCT) at each single study visit. A reduction is thickness indicates an improvement is the lesion area
Time frame: 3 months, 12 month
Proportion of Patients With Angiographic Leakage
Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 3. Also any decreases of angiographic leakage was counted between baseline and 3 month.
Time frame: 3 months, 12 month
Ranibizumab Injection
Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in 3 months of observation period
Time frame: 3 months, 12 month
open-label, single arm study evaluating the safety of 0.5 mg ranibizumab. Patients received individualized ranibizumab intravitreal injections based on evidence of disease activity. The study was early terminated due to low recruitment that hampered to address the primary endpoint of the study
| Milestone | CNV (Choroidal Neovascularization) | ME (Macular Edema) | RI/NVG (Rubeosis Iridis and Neovacular Glaucoma) | PDR/V |
|---|---|---|---|---|
| Started | 93 | 84 | 58 | 35 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 93 | 84 | 58 | 35 |
| Withdrew: Subject's no longer requires study drug | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 5 | 4 | 2 |
| Withdrew: Death | 1 | 0 | 7 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 1 | 13 | 1 | 0 |
| Withdrew: Early termination | 87 | 60 | 43 | 28 |
Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) for ocular and non-ocular events. Due to early termination, only descriptive analysis was conducted.
| Participants | CNV (Choroidal Neovascularization) | ME (Macular Edema) | RI/NVG (Rubeosis Iridis and Neovacular Glaucoma) | PDR/V |
|---|---|---|---|---|
| Non- serious adverse events | 2 | 21 | 1 | 0 |
| Serious adverse events | 11 | 15 | 31 | 14 |
| Death | 1 | 0 | 7 | 1 |
BCVA change for diseases affecting the macular area either through CNV or ME. BCVA is tested using the ETDRS (Early Treatment Diabetic Retinopathy Study), the Snellen or Monoyer scales. The three scales are designed to measure visual acuity. ETDRS score is expressed in letter, Snellen and Monoyer score in fraction. BCVA assessment is presented in ETDRS after conversion if collected in Snellen or Monoyer. (Monoyer converted to Snellen = 2 x (Monoyer fraction) and Snellen converted to approximate ETDRS letters = 1x log(Snellen fraction). ETDRS letter score was transformed in logMAR unit for statistical analysis (- LogMAR = -(ETDRS-85)/50). The worse ETDRS letter score is 0 (logMAR 2.3) and the best ETDRS letter score is 100 (logMAR -0.3).
| Letters | CNV (Choroidal Neovascularization) | ME (Macular Edema) |
|---|---|---|
| 3 Month | 7.3 ± 14.47 | 4.5 ± 11.61 |
| 12 Month | 5.7 ± 12.08 | 5.2 ± 16.46 |
The extent of iris neovascularization was assessed by iris photography and graded using the "Teich and Walsh grading system". This grading system measures the number of quadrant at iris pupillary zone or iris ciliary zone where iris neovascularization (NV) is observed. Grade 0 = "No iris vascularization", Grade 1= Less than 2 quadrants of NV at iris pupillary zone, Grade 2 = More than 2 quadrants of NV at iris pupillary zone, Grade 3 =Grade 2 + less than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae; Grade 4 =More than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae)
| Teich and Walsh grading | Ranibizumab 0.5 mg |
|---|---|
| 3 Month,Grade 0 | 12 |
| 3 Month, Grade 1 | 6 |
| 3 Month, Grade 2 | 8 |
| 3 Month, Grade 3 | 3 |
| 3 Month, Grade 4 | 2 |
| 12 Month, Grade 0 | 11 |
| 12 Month, Grade 1 | 4 |
| 12 Month, Grade 2 | 2 |
| 12 Month, Grade 3 | 4 |
| 12 Month, Grade 4 | 4 |
Occurrence of postoperative vitreous cavity hemorrhage
| Participants | PDR/V |
|---|---|
| 3 Month Absent | 14 |
| 3 Month Present | 3 |
| 12 Month Absent | 12 |
| 12 Month Present | 1 |
CRT in micrometers assessed by Optical Tomography (OCT) at each single study visit. A reduction is thickness indicates an improvement is the lesion area
| μm | CNV (Choroidal Neovascularization) | ME (Macular Edema) |
|---|---|---|
| 3 Month | -54.4 ± 104.55 | -84.4 ± 178.28 |
| 12 Month | -56.4 ± 69.82 | -102.0 ± 220 |
Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 3. Also any decreases of angiographic leakage was counted between baseline and 3 month.
| Participants | CNV (Choroidal Neovascularization) | ME (Macular Edema) | PDR/V |
|---|---|---|---|
| 3 Month Absent | 3 | 3 | 1 |
| 3 Month Present | 3 | 3 | 0 |
| 12 Month Absent | 3 | 1 | — |
| 12 Month Present | 2 | 0 | — |
Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in 3 months of observation period
| Number of injections | CNV (Choroidal Neovascularization) | ME (Macular Edema) | RI/NVG (Rubeosis Iridis and Neovacular Glaucoma) | PDR/V |
|---|---|---|---|---|
| 3 Month | 2.5 ± 1.03 | 2.7 ± 0.88 | 1.7 ± 0.79 | 1.6 ± 1.0 |
| 12 Month | 3.8 ± 2.34 | 3.9 ± 2.17 | 3.0 ± 1.96 | 1.7 ± 1.44 |
Collected over up to 3 years. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Choroidal Neovascularization | 1/93 (1.1%) | 11/93 (11.8%) | 46/93 (49.5%) |
| Macular Edema | 0/84 (0%) | 15/84 (17.9%) | 66/84 (78.6%) |
| Rubeosis Iridis/ Neovascular Glaucoma | 7/58 (12.1%) | 31/58 (53.4%) | 40/58 (69%) |
| Proliferative Diabetic Retinopathy Requiring Vitrectomy | 1/35 (2.9%) | 14/35 (40%) | 21/35 (60%) |
| Event | Choroidal Neovascularization | Macular Edema | Rubeosis Iridis/ Neovascular Glaucoma | Proliferative Diabetic Retinopathy Requiring Vitrectomy |
|---|---|---|---|---|
| Ocular hypertension (Study eye)Eye disorders | 1/93 | 1/84 | 7/58 | 0/35 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/93 | 0/84 | 1/58 | 3/35 |
| Cardiac failureCardiac disorders | 0/93 | 0/84 | 4/58 | 0/35 |
| Retinal detachment (Study eye)Eye disorders | 0/93 | 0/84 | 3/58 | 1/35 |
| Glaucoma (Study eye)Eye disorders | 0/93 | 0/84 | 2/58 | 1/35 |
| Vitreous haemorrhage (Contralateral eye)Eye disorders | 0/93 | 0/84 | 2/58 | 0/35 |
| Vitreous haemorrhage (Study eye)Eye disorders | 0/93 | 2/84 | 2/58 | 1/35 |
| FallInjury, poisoning and procedural complications | 0/93 | 0/84 | 2/58 | 0/35 |
| Intraocular pressure increased (Study eye)Investigations | 0/93 | 1/84 | 2/58 | 0/35 |
| Renal failureRenal and urinary disorders | 0/93 | 0/84 | 2/58 | 1/35 |
| Event | Choroidal Neovascularization | Macular Edema | Rubeosis Iridis/ Neovascular Glaucoma | Proliferative Diabetic Retinopathy Requiring Vitrectomy |
|---|---|---|---|---|
| Drug ineffective (Study eye)General disorders | 3/93 | 27/84 | 1/58 | 0/35 |
| Inappropriate schedule of drug administration (Study eye)Injury, poisoning and procedural complications | 11/93 | 21/84 | 4/58 | 1/35 |
| Eye pain (Study eye)Eye disorders | 6/93 | 5/84 | 7/58 | 3/35 |
| Ocular hypertension (Study eye)Eye disorders | 0/93 | 0/84 | 2/58 | 3/35 |
| HeadacheNervous system disorders | 7/93 | 4/84 | 2/58 | 0/35 |
| Incorrect product storage (Study eye)Injury, poisoning and procedural complications | 4/93 | 6/84 | 1/58 | 0/35 |
| FatigueGeneral disorders | 2/93 | 3/84 | 4/58 | 0/35 |
| Ulcerative keratitis (Study eye)Eye disorders | 0/93 | 1/84 | 2/58 | 2/35 |
| Vision blurred (Study eye)Eye disorders | 2/93 | 1/84 | 0/58 | 2/35 |
| Blood urea increasedInvestigations | 0/93 | 1/84 | 0/58 | 2/35 |
A total of 267 patients who received ranibizumab and had at least one post-baseline efficacy assessment were included in the ITT population.
| Age, Continuous(Years) | CNV (Choroidal Neovascularization) | ME (Macular Edema) | RI/NVG (Rubeosis Iridis and Neovacular Glaucoma) | PDR/V | Total |
|---|---|---|---|---|---|
| Mean | 49.7 ± 16.85 | 64.5 ± 13.99 | 70.9 ± 13.02 | 56.5 ± 9.86 | 59.7 ± 16.62 |
| Sex: Female, Male(Participants) | CNV (Choroidal Neovascularization) | ME (Macular Edema) | RI/NVG (Rubeosis Iridis and Neovacular Glaucoma) | PDR/V | Total |
|---|---|---|---|---|---|
| Female | 48 | 35 | 26 | 17 | 126 |
| Male | 45 | 49 | 30 | 17 | 141 |
Ran from Sep 2013 to primary completion in Jan 2016, 27 months.
Results were first posted in Aug 2019, 3 years 7 months after primary completion.
Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 35. This study's 27 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →